Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-08 | Natasha Hernday has been a director since July 2020. Ms. Hernday is the Executive Vice President of Corporate Development and a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. (NASDAQ: SGEN). She has worked for Seagen since 2011. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers & Acquisitions and as Director, Out-Partnering. She serves on the board of directors of PDL BioPharma, Inc. (NASDAQ: PDLI), the board of directors for Alpine Immune Sciences, Inc. (NASDAQ: ALPN) and on the Knight Campus External Advisory Board for the University of Oregon. Ms. Hernday received her BA in microbiology from the University of California at Santa Barbara and MBA from Pepperdine University. Ms. Hernday brings to the Board extensive experience in advising biotechnology companies on matters of corporate strategy and partnership. |
| 2022-04-07 | Natasha Hernday has been a director since July 2020. Ms. Hernday is the Executive Vice President of Corporate Development and a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. |
| 2023-04-04 | Natasha Hernday has been a director since July 2020... During 2022, the Nominating & Governance Committee consisted of Ms. Hernday (Chair), Ms. Kosacz and Mr. Van Ness. Each member of the Nominating & Governance Committee is independent. The Audit Committee consisted of Mr. Limber (Chair), Ms. Hernday, Mr. Van Ness and Mr. Wyszomierski until February 2022, then Ms. Hernday stepped down, and will rejoin after the annual meeting. |
| 2024-04-02 | Natasha Hernday has been a director since July 2020. During 2023, each non-employee director was entitled to receive an annual retainer of $40,000, plus an additional $6,000 in the case of any other member of the Nominating & Governance Committee. Natasha Hernday total compensation was $207,640. |
Data sourced from SEC filings. Last updated: 2025-08-30